Head to Head Comparison: IRIDEX Corporation (IRIX) vs. The Competition
IRIDEX Corporation (NASDAQ: IRIX) is one of 82 publicly-traded companies in the “Advanced Medical Equipment & Technology” industry, but how does it weigh in compared to its peers? We will compare IRIDEX Corporation to similar companies based on the strength of its valuation, earnings, risk, dividends, analyst recommendations, institutional ownership and profitability.
Institutional & Insider Ownership
47.5% of IRIDEX Corporation shares are owned by institutional investors. Comparatively, 53.1% of shares of all “Advanced Medical Equipment & Technology” companies are owned by institutional investors. 5.0% of IRIDEX Corporation shares are owned by insiders. Comparatively, 16.8% of shares of all “Advanced Medical Equipment & Technology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Earnings & Valuation
This table compares IRIDEX Corporation and its peers gross revenue, earnings per share and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|IRIDEX Corporation||$42.80 million||-$5.81 million||-6.25|
|IRIDEX Corporation Competitors||$2.02 billion||$430.75 million||-69.39|
IRIDEX Corporation’s peers have higher revenue and earnings than IRIDEX Corporation. IRIDEX Corporation is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Risk & Volatility
IRIDEX Corporation has a beta of 1.29, meaning that its share price is 29% more volatile than the S&P 500. Comparatively, IRIDEX Corporation’s peers have a beta of 0.89, meaning that their average share price is 11% less volatile than the S&P 500.
This is a breakdown of recent ratings and target prices for IRIDEX Corporation and its peers, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|IRIDEX Corporation Competitors||417||2186||3396||123||2.53|
IRIDEX Corporation currently has a consensus price target of $20.00, indicating a potential upside of 112.09%. As a group, “Advanced Medical Equipment & Technology” companies have a potential downside of 20.15%. Given IRIDEX Corporation’s stronger consensus rating and higher possible upside, equities analysts plainly believe IRIDEX Corporation is more favorable than its peers.
This table compares IRIDEX Corporation and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|IRIDEX Corporation Competitors||-332.41%||-33.62%||-12.57%|
IRIDEX Corporation Company Profile
IRIDEX Corporation is a provider of therapeutic based laser consoles, delivery devices and consumable instrumentation used to treat sight-threatening eye diseases in ophthalmology. The Company operates through ophthalmology segment. Its ophthalmology products consist of laser consoles, delivery devices and consumable instrumentation, including laser probes, and are used in the treatment of serious eye diseases, including the over three causes of irreversible blindness, such as diabetic retinopathy, glaucoma and age-related macular degeneration (AMD). In addition, the Company’s ophthalmology products are often used in vitrectomy procedures (used to treat proliferative diabetic retinopathy, macular holes, retinal tears and detachments), which are generally performed in the operating room and require a consumable single use intraocular laser probe (EndoProbe) to deliver light to the back of the eye together with other instrumentation.
Receive News & Ratings for IRIDEX Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IRIDEX Corporation and related companies with MarketBeat.com's FREE daily email newsletter.